不同克隆号Ki-67对乳腺癌免疫组化染色的性能分析  

Performance Analysis of Immunohistochemical Staining for Breast Cancer using Different Ki-67 Clones

作　　者：陈耿标[1] 刘映芬[2] 李海刚[1] 孙情[1] 沈溪明[1] 杨敏 CHEN Geng-biao;LIU Ying-fen;LI Hai-gang;SUN Qing;SHEN Xi-ming;YANG Min(Pathology Dept.Of Sun Yat-sen memorial Hospital of Sun Yat-sen University,Guangzhou 510120;Guangdong Provincial Hospital of Chinese Medicine,Guangzhou)

机构地区：[1]中山大学孙逸仙纪念医院病理科,510120 [2]广东省中医院

出　　处：《岭南急诊医学杂志》2024年第5期532-534,共3页Lingnan Journal of Emergency Medicine

摘　　要：目的:研究不同克隆号Ki-67在乳腺浸润性导管癌组织的表达百分比。方法:收集2022年-2023年,中山大学孙逸仙纪念医院病理科收录的45例乳腺浸润性导管癌患者资料,采用免疫组化方法对其Ki-67表达情况进行探讨,通过对比分析,比较不同克隆号Ki-67在乳腺癌中增值指数百分比的差异。结果:本次45例分析结果得出抗体克隆号分组中,MIB1、C3G4、30-9和UMAB107组Ki-67增殖指数百分比分别为10.97(5.12,27.82)、4.74(2.17,14.97)、16.09(4.73,29.51)和9.87(4.24,26.56),差异有统计学意义。结论:抗体克隆号的选择对乳腺癌中Ki-67免疫组化染色结果有较大影响,不同克隆号Ki-67抗体在乳腺癌中的增值指数百分比有显著性差异,Ki-67(30-9)和(MIB1)克隆号在乳腺癌中具有较高且稳定的表达,推荐在乳腺癌Ki-67免疫组化检测流程中使用30-9和MIB1这两个克隆号。Objective:To investigate the expression percentage of different Ki-67 clones in breast invasive ductal carcinoma tissue.Methods:Data from 45 patients with invasive ductal carcinoma of the breast admitted to the Department of Pathology at Sun Yat-sen Memorial Hospital of Sun Yat sen University from 2022 to 2023 were collected.Immunohistochemical methods were used to explore the expression of Ki-67 in these patients.Through comparative analysis,the difference of increment index percentage of different clone Ki-67 in breast cancer was compared.Results:In this analysis of 45 cases,statistically significant differences werenoticed between the median proliferation index of Ki-67 in MIB1,C3G4,30-9,and UMAB107(the median proliferation index,10.97,4.74,16.09,and 9.87,respectively).Conclusion:The selection of antibody clone has great influence on Ki-67 immunohistochemical staining results in breast cancer,The percentage of positive cells of Ki-67 antibodies with different clones in breast cancer was significantly different,Ki-67(30-9)and(MIB1)have high and stable expression in breast cancer.It is recommended to use 30-9 and MIB1 in breast cancer Ki-67 immunohistochemical detection process.

关 键 词：乳腺浸润性导管癌 不同克隆号Ki-67 一致性分析 

分 类 号：R737.9[医药卫生—肿瘤]